Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $24.00.

A number of research analysts recently issued reports on ZVRA shares. Wall Street Zen lowered shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 20th. HC Wainwright started coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 price objective for the company. JMP Securities dropped their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a report on Wednesday, August 13th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Finally, Zacks Research lowered shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th.

Zevra Therapeutics Trading Down 8.7%

ZVRA opened at $10.12 on Thursday. The stock has a market capitalization of $568.04 million, a price-to-earnings ratio of -48.19 and a beta of 1.49. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52. Zevra Therapeutics has a twelve month low of $6.19 and a twelve month high of $13.16. The company has a 50-day simple moving average of $9.50 and a 200 day simple moving average of $9.43.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($1.49). The company had revenue of $25.88 million during the quarter, compared to analyst estimates of $22.49 million. Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. Analysts predict that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Activity at Zevra Therapeutics

In other news, Director John B. Bode purchased 5,000 shares of the stock in a transaction on Tuesday, August 19th. The stock was purchased at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the acquisition, the director owned 45,000 shares in the company, valued at $412,200. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil F. Mcfarlane sold 19,500 shares of the firm’s stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $10.82, for a total transaction of $210,990.00. Following the transaction, the chief executive officer owned 222,016 shares of the company’s stock, valued at approximately $2,402,213.12. The trade was a 8.07% decrease in their position. The SEC filing for this sale provides additional information. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ZVRA. GAMMA Investing LLC raised its holdings in Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after purchasing an additional 8,020 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Zevra Therapeutics by 11.0% during the 1st quarter. Bank of New York Mellon Corp now owns 120,433 shares of the company’s stock worth $902,000 after buying an additional 11,946 shares during the period. Mystic Asset Management Inc. grew its position in shares of Zevra Therapeutics by 8.2% during the 1st quarter. Mystic Asset Management Inc. now owns 338,902 shares of the company’s stock worth $2,538,000 after buying an additional 25,555 shares during the period. AIGH Capital Management LLC grew its position in shares of Zevra Therapeutics by 82.4% during the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after buying an additional 649,495 shares during the period. Finally, Readystate Asset Management LP grew its position in shares of Zevra Therapeutics by 924.6% during the 1st quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock worth $5,116,000 after buying an additional 616,370 shares during the period. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.